Disclosure and authorship. Written by Semaine Health. We make one of the products compared here. Competitor formula, price, and subscription facts in this guide were retrieved on July 27, 2026. Package counts differ between brands, so listed prices are not directly comparable per serving. Tell us if something is out of date.
This guide compares four daily urinary-health supplements. Supplements do not replace evaluation or clinician-directed care for an active UTI.
The short answer
Start with one fact that reorganizes this whole category: Uqora, URO, and AZO all use the same cranberry ingredient. All three list 500 mg of Pacran whole-fruit cranberry, from the $7.99 drugstore caplet up to URO at $31.99. None of the three declares how much proanthocyanidin, the active cranberry compound, that 500 mg actually delivers, or by what assay it was measured.
Semaine UTC&P is built the other way around. It uses Anthocran Phytosome from Indena, a named, standardized ingredient with two published human studies behind it at the exact 120 mg daily dose on our label, plus a study of the finished product. Utiva is the one competitor here that declares its PAC number honestly, 36 mg measured by DMAC/A2, at the highest price of the four, though its trial compared two doses rather than a placebo and missed significance on its primary comparison.
What is in each
| Product | Cranberry ingredient | PAC quantity and assay declared | Other actives | Evidence on that ingredient | Listed price |
|---|---|---|---|---|---|
| Semaine UTC&P | Anthocran Phytosome (Indena), 120 mg | Standardized to 6% to 9% PACs by DMAC spectrophotometry | Hibiscus 4:1 extract 240 mg | Two published human studies on this branded ingredient at 120 mg, including a placebo-controlled RCT; plus a Semaine-funded study of the finished formula | $30.99 one-time; about $27.98 monthly, about $23.30 every 3 months |
| Uqora Flush Advanced+ | Pacran whole fruit, 500 mg | None declared | D-mannose 2,000 mg | Ingredient-level qualified claim; no finished-formula trial identified | $29.99 one-time; $26.99 subscription |
| Utiva Cranberry PACs | Cranberry extract, 36 mg PACs | 36 mg, soluble PACs by DMAC/A2 | None | 145-woman dose-comparison trial; primary comparison not significant | $39.99 one-time; $29.99 subscription |
| URO (O Positiv) | Pacran whole fruit, 500 mg | None declared | D-mannose 500 mg; vitamin C 100 mg | Ingredient-level claims only; page states no study of the finished product | $31.99 one-time; $26.99 subscription |
Prices can change and exclude tax and shipping. Uqora's price-to-packet-count mapping was not fully exposed at retrieval, so a like-for-like cost per serving cannot be calculated across all four from public pages alone.
Why 9 mg of PACs can do the work of 36 mg
The obvious objection to Semaine is that 120 mg of cranberry phytosome standardized to 6% to 9% PACs delivers roughly 9 mg of PACs, while Utiva declares 36 mg. On a label that looks like four times less.
Delivery form is why that comparison does not hold. A phytosome binds cranberry's active compounds to phospholipids so more of them survive digestion and reach tissue rather than passing through. Indena, which manufactures the ingredient, states the comparison directly: "Anthocran Indena Phytosome delivering 9 mg of PACs (proanthocyanidins) has proved to be as effective as unformulated products containing 36 mg of them" (Indena, retrieved July 27, 2026). That is the manufacturer's characterization of its own technology, and it is worth reading as such. What supports it independently is that the 120 mg dose, not a larger one, is the dose that produced results in two published human studies.
The practical takeaway is that cranberry milligrams and PAC milligrams are not comparable across delivery forms. A bigger number on a label does not mean more active compound reaches you, which is why the useful questions are which specific ingredient was studied, at what dose, and measured how.
Semaine UTC&P: what the evidence shows
UTC&P provides 120 mg of Anthocran Phytosome, the branded cranberry ingredient made by Indena, standardized to 6% to 9% PACs by DMAC spectrophotometry, plus 240 mg of hibiscus 4:1 extract, in one capsule daily. Indena's recommended dose for the ingredient is 120 mg per day, which is what the label provides. It is $30.99 one-time, and subscription reduces that by 9.7% monthly, 19.4% every two months, or 24.8% every three months, bringing the every-three-months price to roughly $23.30 (product page and Indena, retrieved July 27, 2026).
Being able to name the manufacturer, the branded ingredient, the standardization percentage, and the assay method is not universal in this category. Utiva can name its PAC quantity and assay. Uqora, URO, and AZO name a branded ingredient and stop there.
Two human studies on the exact ingredient
A 2024 double-blind, placebo-controlled RCT tested 120 mg of the cranberry phytosome in postmenopausal women with type 2 diabetes taking SGLT-2 inhibitors; 46 completed it, 23 per arm. Over six months UTI episodes rose in the placebo group while staying flat on supplementation, with the time-by-supplementation interaction significant at p=0.001, and at the four-month follow-up 9% of the placebo group showed infection versus 3% on supplementation. The authors concluded the standardized cranberry extract phytosome reduced UTI recurrence. The population was unusually specific, and the trial tested the ingredient rather than the finished UTC&P formula (Rondanelli 2024, PMID 38999860).
A 2021 study tested the same branded ingredient at the same 120 mg daily dose in 64 patients requiring post-surgical catheterization, against standard management and against nitrofurantoin. The cranberry groups reported greater reduction in UTI symptoms than either comparator, with decreased hematuria and urine bacterial contamination (p<0.05), and no participant in that group had a recurrent UTI in the three months after the study ended (p<0.05). This was a preliminary pilot registry study rather than a randomized trial, with small arms and Indena research staff among the authors, so it carries less weight than the RCT. It is nonetheless a second published human result on this specific ingredient at this specific dose (Cotellese 2021, PMID 34632933).
And a study of the finished product
Semaine also studied the formula people actually buy, which none of the three compared brands published for their own products in the pages reviewed here. It was a five-month consumer-perception study of 48 women age 40 and older, conducted by Citrus Labs and funded by Semaine. It was open-label, not randomized, and had no placebo group, so it reports participant experience rather than establishing causation (clinical trials, retrieved July 27, 2026).
Uqora and URO: the same cranberry, plus D-mannose
Uqora states that one Flush Advanced+ packet daily supplies 2,000 mg D-mannose and 500 mg whole-fruit Pacran cranberry, at $29.99 one-time or $26.99 by subscription renewing every four weeks (product page, retrieved July 27, 2026). Its cranberry disclosure carries the FDA-qualified claim that consuming 500 mg daily may help reduce the risk of recurrent UTI in healthy women, alongside FDA's own conclusion that the scientific evidence supporting that claim is limited (ingredients, retrieved July 27, 2026).
URO supplies, per two-capsule serving, 500 mg of the same Pacran whole-fruit cranberry, 500 mg D-mannose, and 100 mg vitamin C, at $31.99 one-time or $26.99 by monthly subscription. Pacran at 500 mg does have a 2025 placebo-controlled trial behind it, which studied the ingredient rather than any finished product. URO's page states clinical support for its ingredients, not for the finished URO formula, and declares no PAC quantity or assay (product page, retrieved July 27, 2026; 2025 Pacran trial).
What does current D-mannose evidence show?
D-mannose has a plausible anti-adhesion mechanism, and earlier small studies reported benefit, but newer higher-quality evidence is less favorable. In the largest placebo-controlled trial to date, 2 g daily did not significantly reduce medically attended, clinically suspected recurrent UTIs over six months: 51.0% with D-mannose versus 55.7% with placebo, a risk difference of -5 percentage points (95% CI -13 to 3; P=.26) (MERIT, PMID 38587819).
Recent peer-reviewed meta-analyses, which pool older favorable trials together with newer negative ones, likewise did not find a statistically convincing reduction: RR 0.57 (95% CI 0.29 to 1.15) and RR 0.44 (95% CI 0.18 to 1.11; P=.082), with high heterogeneity (Vargas 2025, PMID 41004704; Krishna 2025, PMID 41195062). Those intervals cross 1.0, so they do not prove absence of benefit in every population, and a 2024 network meta-analysis reported a favorable indirect estimate, RR 0.34 (95% CI 0.21 to 0.56) (PMID 39095666).
Dose matters when applying any of it. Uqora provides 2,000 mg, matching the dose used in MERIT and most pooled trials, so that evidence speaks fairly directly to it. URO provides 500 mg, roughly a quarter of that, which means neither the older favorable studies nor the recent null ones tested what is in the bottle. Among the products here, this evidence applies to Uqora and URO. Utiva does not list D-mannose, and Semaine UTC&P does not contain D-mannose.
Utiva: what the evidence shows
Utiva declares 36 mg of proanthocyanidins per serving with soluble PACs measured by DMAC/A2, in a 30-capsule bottle taken as one capsule daily for maintenance, at $39.99 one-time or $29.99 by subscription. Variants displayed as sold out or unavailable at retrieval (product page, retrieved July 27, 2026). Declaring the PAC number and the assay is a genuine transparency advantage over Uqora, URO, and the drugstore options.
Its cited trial randomized 145 women with a history of recurrent UTI to 37 mg PAC daily or a 2 mg low-dose control for 24 weeks, not against placebo. The primary comparison was not statistically significant overall. A subgroup with fewer than five infections in the prior year had fewer symptomatic episodes, and subgroup findings carry less weight than a primary result. The study tested a standardized cranberry extract, not an identified finished Utiva product (paper, retrieved July 21, 2026).
Where drugstore cranberry fits
Mass-market cranberry caplets, of which AZO is the best known, cost roughly a third as much per day and use the same Pacran ingredient as Uqora and URO. If price is the deciding factor, that is a reasonable place to start, and the ingredient has a recent placebo-controlled trial behind it. What it shares with the two premium Pacran products is the absence of a declared PAC quantity or assay method. Paying more did not buy more disclosure.
Which one fits whom
- Semaine may fit someone who wants a named, standardized cranberry ingredient with two published human studies at the dose on the label, an absorption-optimized delivery form, and one capsule a day, with subscription pricing that falls by up to 24.8%. It asks you to accept that the RCT population was unusually specific and that the finished-product study was uncontrolled.
- Utiva may fit someone who wants a declared, assay-measured PAC number above all else, accepting the highest price of the four and a trial that missed significance on its primary comparison.
- Uqora may fit someone who specifically wants a full 2 g of D-mannose in a drink mix, having weighed the current D-mannose evidence.
- URO may fit someone who wants Pacran with added vitamin C in capsule form, accepting no declared PAC quantity and a D-mannose dose well below the studied one.
No supplement should delay care for a suspected infection, fever, side or back pain, blood in urine, pregnancy, or persistent symptoms.
Frequently asked questions
Isn't 36 mg of PACs better than 9 mg?
Not necessarily, because the two numbers describe different delivery forms. Indena, which manufactures the cranberry phytosome Semaine uses, states that its ingredient delivering 9 mg of PACs has proved as effective as unformulated products containing 36 mg, because the phospholipid phytosome improves how much survives digestion. That is the manufacturer's claim about its own technology. What supports it independently is that 120 mg, the dose delivering roughly 9 mg of PACs, is the dose that produced results in two published human studies rather than a larger one.
Do any of these products share the same cranberry ingredient?
Yes. Uqora, URO, and AZO all list 500 mg of Pacran whole-fruit cranberry, spanning a price range from about $7.99 to $31.99. None of the three declares how much proanthocyanidin that 500 mg delivers, or the assay used to measure it. Semaine uses a different ingredient, Anthocran Phytosome from Indena, and Utiva uses a cranberry extract standardized to a declared 36 mg of PACs.
Which of these products declares how much PAC it contains?
Utiva declares 36 mg measured by DMAC/A2. Semaine declares 120 mg of a phytosome standardized to 6% to 9% PACs by DMAC spectrophotometry, roughly 9 mg of PACs. Uqora and URO declare whole-fruit cranberry weight only, with no PAC quantity and no assay method.
Which of these has evidence for the finished formula, not just an ingredient?
Only Semaine, among the pages reviewed here. Every product compared rests on evidence for an ingredient rather than for the product in the bottle. Semaine additionally ran a five-month study of finished UTC&P in 48 women age 40 and older, though it was open-label, uncontrolled, and Semaine-funded, so it reports participant experience rather than proving cause.
Is 500 mg of D-mannose enough?
The trials that tested D-mannose for prevention generally used about 2 g daily, which is what Uqora provides. URO provides 500 mg, roughly a quarter of that, so the published evidence, favorable and null alike, did not test that amount. The 2 g dose itself did not show a statistically significant reduction in the largest placebo-controlled trial.
Does Semaine have randomized evidence?
Yes, at the ingredient level. Its 120 mg Anthocran Phytosome was tested in a double-blind, placebo-controlled RCT in postmenopausal women with type 2 diabetes taking SGLT-2 inhibitors, with 46 completers, where UTI episodes rose on placebo and stayed flat on supplementation, a time-by-supplementation interaction significant at p=0.001. A second published study tested the same ingredient at the same dose after catheterization. Both studied the ingredient, not the finished UTC&P formula.
Is cranberry or D-mannose better for daily UTI prevention?
Current direct evidence favors prioritizing a transparent, standardized cranberry ingredient over D-mannose. The largest placebo-controlled D-mannose trial and recent conventional meta-analyses did not find a statistically convincing reduction in recurrence, though a favorable network meta-analysis means the total evidence is mixed rather than uniformly negative. This is an ingredient-level comparison and does not establish that every cranberry product works or that every D-mannose dose fails.
Can these supplements treat an active UTI?
No. These products are sold for urinary-health support. The limited FDA-qualified risk-reduction language discussed above applies specifically to products presenting the 500 mg whole-cranberry claim, including the reviewed Uqora page. It is not a treatment claim and does not apply to every compared product. Seek diagnosis and clinician-directed care for a suspected active infection.
Are cranberry PAC milligrams interchangeable?
No. Source, extraction, standardization, testing method, dose, and delivery form all differ. Check whether the research behind a product used the same ingredient at the same dose.
Sources
- Semaine Urinary Tract Cleanse & Protect and Semaine clinical trials (retrieved July 27, 2026)
- Indena, Anthocran Phytosome (retrieved July 27, 2026)
- Uqora Flush Advanced+ and Uqora ingredients (retrieved July 27, 2026)
- Utiva Cranberry PACs Supplement (retrieved July 27, 2026)
- O Positiv URO Urinary Tract Health Capsules (retrieved July 27, 2026)
- Rondanelli 2024, PMID 38999860; Cotellese 2021, PMID 34632933; PACCANN trial; 2025 Pacran trial
- MERIT, PMID 38587819; Vargas 2025, PMID 41004704; Krishna 2025, PMID 41195062; network meta-analysis, PMID 39095666
